Update 1989 pp 411-422 | Cite as

Blood Component Therapy in the Critically Ill

  • J. P. Isbister
Conference paper
Part of the Update in Intensive Care and Emergency Medicine book series (UICM, volume 8)

Abstract

Blood component therapy remains one of the greatest advances in modern medicine. It has not only been a major contribution to survival from hemorrhagic shock, but has also allowed complex surgery to develop and specific congenital and acquired hemopoeitic deficiency states to be temporarily corrected. Blood component therapy is one of the most important ‘weapons’ in the intensivist’s armentarium [1]. It is important that critical care physicians clearly understand the diagnosis and management of hemopoeitic defects, the composition of the various blood components and to carefully analyse the risk/benefit equation in the use of blood products. The correctly identified, appropriately administered and timely blood component can be lifesaving. It should, however, be emphasized that blood component therapy is similar to many aspects of critical care medicine where interim support is being provided for the patient to survive a potentially lethal organ malfunction, in order for other appropriate corrective medical therapy or surgery to be applied and for the body’s host defense system to initiate its appropriate responses and establish healing. In some circumstances, the basic underlying pathophysiology for the patient’s illness may be poorly understood and a definitive diagnosis may not have been made.

Keywords

Toxicity Depression Lactate Citrate Anemia 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Isbister JP (1985) Blood component therapy in clinical medicine. Blackwell, MelbourneGoogle Scholar
  2. 2.
    Insalaco S, Menitove J (1987) Transfusion-transmitted viruses: Epidemiology and pathology. Am Assoc of Blood BanksGoogle Scholar
  3. 3.
    Peterman TA (1987) Transfusion-associated acquired immunodeficiency syndrome. World J Surg 11:36–40CrossRefGoogle Scholar
  4. 4.
    Isbister JP (1985) Strategies for avoiding or minimizing homologous blood transfusion: A sequel to the AIDS scare. Med J Aust 142:596–599PubMedGoogle Scholar
  5. 5.
    Isbister JP (1984) Blood transfusion and blood component therapy. Clin Anesth 2:643–666Google Scholar
  6. 6.
    Maetani S, Nishikawa T, Tobe T, Hirakawa A (1986) Role of blood transfusion in organ system failure following major abdominal surgery. Ann Surg 203:275–281PubMedCrossRefGoogle Scholar
  7. 7.
    Collins JA (1987) Recent developments in the area of massive transfusion. World J Surg 11:75–81PubMedCrossRefGoogle Scholar
  8. 8.
    Reed RL, Ciavarella D, Heimback DM, et al (1986) Prophylactic platelet administration during massive transfusion. Ann Surg 203:40–48PubMedCrossRefGoogle Scholar
  9. 9.
    National Institutes of Health, Bethesda, MD (1987) Fresh frozen plasma. Indications and risks. Transfusion Medicine Reviews: 1:201–204CrossRefGoogle Scholar
  10. 10.
    National Institute of Health Bethesda, MD (1987): Platelet transfusion therapyGoogle Scholar
  11. 11.
    Ciavarella D, Reed RL, Counts RB, et al (1987) Clotting factor levels and the risk of diffuse microvascular bleeding in the massively transfused patient. Br J Hematol 67:365–368CrossRefGoogle Scholar
  12. 12.
    Harrigan C, Lucas CE, Ledgerwood AM, Walz DA, Mammen EF (1985) Serial changes in primary hemostasis after massive transfusion. Surgery 98:836–843PubMedGoogle Scholar
  13. 13.
    Phillips T, Soulier G, Wilson R (1987) Outcome of massive transfusion exceeding two blood volumes in trauma and emergency surgery. J Trauma 27:903–910PubMedCrossRefGoogle Scholar
  14. 14.
    Tartter PI (1988) Blood transfusion and infectious complications following colorectal cancer surgery. Br J Surgery 75:789–792CrossRefGoogle Scholar
  15. 15.
    George CD, Morello PJ (1986) Immunological effects of blood transfusion upon renal transplantation, tumor operations, and bacterial infections. Am J Surg 152:329–337PubMedCrossRefGoogle Scholar
  16. 16.
    Wu HS, Little AG (1988) Perioperative blood transfusions and cancer recurrence. J Clin Onco 6:1348–1354Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • J. P. Isbister

There are no affiliations available

Personalised recommendations